We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




New Collaboration to Apply Power of AI to Digital Pathology Images

By LabMedica International staff writers
Posted on 30 Jan 2023

Clinical artificial intelligence (AI) applications have the potential to help pathologists diagnose cancer more confidently and efficiently, ultimately improving patient care. Now, a new collaboration aims to lead the digital transformation of pathology and cancer diagnosis.

Microsoft (Redmond, WA, USA) and Paige (New York, NY, USA) have entered into a collaboration to apply the power of AI to digital pathology images for developing and delivering a new generation of clinical applications and computational biomarkers to transform cancer diagnosis and patient care. Microsoft will also make a strategic investment in Paige to accelerate the development and deployment of life-saving AI diagnostics. Through the collaboration, Paige and Microsoft will scale Paige’s technology globally and accelerate the adoption of AI in digital pathology.

Paige puts the power of AI into the hands of pathologists by developing novel AI applications on a powerful platform, making it easy to deploy AI in laboratories globally. Paige is currently the only company to have received FDA approval for an AI algorithm in pathology. Paige will use Microsoft Azure as its cloud provider for the Paige Platform, a comprehensive solution to power a lab’s digital pathology workflow that consists of data management, cloud storage options and FullFocus, an FDA-cleared whole-slide image viewer. As part of this collaboration, Paige will become a Microsoft Cloud for Healthcare partner and enable Microsoft to enhance its own offerings for healthcare customers.

Paige will work with other entities, including Microsoft Research on developing large scale machine learning models to push the boundaries of research in oncology and pathology. Paige is also working with Nuance, a Microsoft company, on integrating their offering with Nuance’s Precision Imaging Network. Paige technology will be offered as a partner solution in Microsoft Cloud for Healthcare, expanding access to cutting-edge digital cancer diagnostic tools. Microsoft Cloud for Healthcare connects customers with trusted partner solutions that make it easier to create personalized patient experiences, give clinicians connected tools, and adopt data standards important to healthcare. Together with Nuance, healthcare organizations can access the broadest and deepest set of trusted AI solutions to address the biggest challenges in the industry. Paige becoming a Microsoft Cloud for Healthcare partner extends the solution’s robust capabilities and helps it reach new customers.

“We are thrilled to partner with Microsoft to make AI cancer diagnostics accessible to countless laboratories and hospitals around the world as part of the digital transformation of pathology,” said Andy Moye, Ph.D., Chief Executive Officer at Paige. “We believe that Microsoft’s world-class AI resources, cloud infrastructure, global reach and scale, combined with our deep expertise in developing AI cancer diagnostics, will drive a new era of diagnostics and precision treatment to improve the lives of patients.”

"The application of technology to help clinicians and researchers further enhance patient care and, in many cases, provide life-saving treatment is a core tenet for Microsoft in health and life sciences,” said Tom McGuinness, corporate vice president, Global Healthcare & Life Sciences, Microsoft. “We look forward to further collaborating with Paige and giving Microsoft Cloud for Healthcare customers the ability to harness the power and promise of AI in digital pathology.”

Related Links:
Microsoft
Paige

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.